Soft Tissue Sarcomas: Descriptive Study of 232 Cases Collected, over a Period of 10 Years, at the Hospital of Oncology, Department of the Hassan II Hospital FEZ
- 1 Faculty of Medicine of Fez, University Hospital Center Hassan II, Fez, Morocco
- 2 Faculty of Medicine of Fez, University Hospital Center Hassan II, Fez, Morocco
- 3 Faculty of Medicine of Fez, University Hospital Center Hassan II, Fez, Morocco
- 4 Faculty of Medicine of Fez, University Hospital Center Hassan II, Fez, Morocco
- 5 Faculty of Medicine of Fez, University Hospital Center Hassan II, Fez, Morocco
- 6 Faculty of Medicine of Fez, University Hospital Center Hassan II, Fez, Morocco
- 7 Faculty of Medicine of Fez, University Hospital Center Hassan II, Fez, Morocco
- 8 Faculty of Medicine of Fez, University Hospital Center Hassan II, Fez, Morocco
Abstract
Soft-tissue sarcomas are uncommon tumors that have traditionally been managed by wide excisional surgery and radiotherapy; the use of chemotherapy has been reserved for advanced disease. Advances in multidisciplinary care have improved the evaluation and care of patients with this disease. Limb-conserving surgical paradigms, superior radiotherapy delivery, and novel adjuvant agents for specific tumors are now available. The objective of this study is to report the epidemiological, clinical, histological, therapeutic and evolutionary characteristics of soft tissue sarcomas at the oncology hospital: Chu Hassan II in FEZ, and to define the factors influencing patient survival. This is a retrospective study of 232 cases of soft tissue sarcoma, collected between January 2010 and June 2020. The eligibility criteria were an age greater than 16 years, and histological evidence of a soft tissue sarcoma excluding gastrointestinal stromal tumors (GIST). Items collected were: epidemiological, clinical, histological, radiological, and therapeutic. These are 232 cases, 120 Men and 112 Women, the mean age was 48.89 years (Extreme = 18 - 76 years). The tumor was localized to the extremities at (58.72%). The predominant histological type was Leiomyosarcoma in 61 cases (26.29%). The tumor stage was localized in (17.67%) of cases, locally advanced in 34.05% and metastatic in 44.08% of patients, all localized cases were treated surgically including (84%) conservative surgery and (16%) radical surgery. Radiation therapy was performed in 32.75% of patients. Chemotherapy was performed in 74.14% of patients. Age and tumor stage are prognostic factors influencing the survival of soft tissue sarcomas.
- Bonvalot, S., Vanel, D., Terrier, P., Le Pechoux, C., et al. (2004) Principles for the Treatment of Soft Tissue Sarcoma in Adults. EMC-Rhumatologie-Orthopédie, 1, 521-541. https://doi.org/10.1016/j.emcrho.2004.08.001
- ESMO/European Sarcoma Network Working Group (2014) Soft Tissue and Visceral Sarcomas: ESMO Clinical Practice Guidelines for diagnosis, Treatment and Follow-Up. Annals of Oncology, 25, III102-III112.
- Derbel, O., Cropet, C., Meeus, P., Gilly, F.-N., et al. (2012) Adhesionto Clinical Practices Guidelines (CPG’S) and Role on Survival Forsoft Tissue Sarcoma Patients: Analysis of a Population Basedcohort from Rhone-Alpes Region. Annals of Oncology, 23, 478-491. https://doi.org/10.1093/annonc/mds414
- Morère, J.F., Mornex, F. and Soulières, D. (2011) Thérapeutique du Cancer. 2nd Edition, Springer-Verlag, Paris. https://doi.org/10.1007/978-2-8178-0021-9
- Bui-Nguyen, B., Italiano, A., Delva, F. and Toulmond, M. (2010) Adjuvant Chemotherapy of Adults Soft Tissue Sarcomas. Bulletin du Cancer, 97, 673-678.
- Le Cesne, A., Ouali, M., Leahy, M.G., Santoro, A., Hoekstra, H.J., et al. (2014) Doxorubicinbased Adjuvant Chemotherapy in Soft Tissue Sarcoma: Pooledanalysis of Two STBSG-EORTC Phase III Clinical Trials. Annals of Oncology, 25, 2425-2432. https://doi.org/10.1093/annonc/mdu460
- Rodrigo, R.-S., Nathalie, A., Elodie, T., Gonzalo, G.-A., et al. (2011) Topoisomerase II-Alpha Protein Expression and Histological Response Following Doxorubicin-Based Induction Chemotherapy Predict Survival of Locally Advanced Soft Tissues Sarcomas. European Journal of Cancer, 47, 1319-1327. https://doi.org/10.1016/j.ejca.2011.02.010
- Italiano, A., Toulmonde, M. and Bui-Nguyen, B. (2010) Chemotherapy Options for Patients with Advanced Soft-Tissue Sarcoma beyond Anthracyclines. Bulletin du Cancer, 97, 679-686.
- Chawla, S.P., Papai, Z., Mukhametshina, G., Sankhala, K., et al. (2015) First-Line Aldoxorubicin vs Doxorubicin in Metastatic or Locally Advanced Unresectable Soft-Tissue Sarcoma: A Phase2b Randomized Clinical Trial. JAMA Oncology, 1, 1272-1280. https://doi.org/10.1001/jamaoncol.2015.3101
- Pautier, P.a, Floquet, A., Chevreau, C., et al. (2015) Trabectedin in Combination with Doxorubicin for First-Line Treatment of Advanced Uterine or Soft-Tissue Leiomyosarcoma (LMS-02): Anon-Randomised, Multicentre, Phase 2 Trial. The Lancet Oncology, 16, 457-464. https://doi.org/10.1016/S1470-2045(15)70070-7
- Penel, N., Watelle, F., Vanhuyse, M. and Adenis, A. (2010) Traitement dessarcomes des tissus mous de l’adulte métastatiques: Evolution actuelle des concepts. Bulletin du Cancer, 97, 687-691.